ALX Oncology Inc. has developed ALX-2004, an antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR) with a topoisomerase I inhibitor payload, for treating EGFR+ cancer solid tumors.
Interleukin 1 receptor accessory protein (IL1RAP) is a receptor that activates signaling pathways triggered by IL1α/β, IL33 and IL36α/β/γ, which are involved in several autoimmune or inflammatory disorders, including psoriasis, gout or systemic sclerosis. Innovent Biologics Co. Ltd. presented data for their anti-IL1RAP antibody IBI-3011, a fully humanized IgG1 antibody targeting IL1RAP that blocks those pathways.
The prevalence of valvular heart disease in the U.S. is tough to peg with any great precision, but an extrapolation of data from a new study would put the number at roughly 10.6 million people, a staggering number when the clinical and fiscal implications are considered.
Shooting for further proof of durable, drug-free, disease-free remission with a single dose of KYV-101 in generalized myasthenia gravis, Kyverna Therapeutics Inc. plans to start phase III work by the end of this year. The Emeryville, Calif.-based firm rolled out positive interim results from the phase II portion of the registrational Kysa-6 clinical trial testing the drug, a fully human, autologous, CD19 CAR T-cell therapy with CD28 costimulation.
Cyclin-dependent kinases (CDKs) are interesting targets in metastatic cancers. Oncobone Therapeutics Ltd. recently presented data on a new CDK9/13 dual inhibitor – OBP-004 – as a potential approach for treating metastatic cancers.
CDR-609 is a T-cell engager therapeutic from CDR-Life Inc. that targets Leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) with potential for treating colorectal cancer.
Leading advances in cancer research, the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics highlighted some of the field’s most promising innovations. Parabilis Medicines Inc. and Tango Therapeutics Inc. presented their work on potential therapeutic targets that may signal significant shifts in the future of cancer treatment.
Stakeholders of all stripes have wondered whether transcatheter aortic valve replacement devices could match their surgically implanted cousins for device durability, but seven-year data from the Partner 3 trial seems to suggest that patients, physicians, payers and regulators need not fret as the topline numbers showed no statistically significant difference for outcomes such as mortality and morbidity.
Medtronic plc’s SPYRAL HTN-ON MED trial demonstrated significantly greater reduction in blood pressure with the Symplicity Spyral renal denervation procedure at three years than a sham procedure in a study presented as featured clinical research at the 2025 Transcatheter Cardiovascular Therapeutics conference in San Francisco.
Cordis Corp. has quite a bit to crow about in this latter part of October 2025 with the unveiling of results of two studies that back the Miami Lakes, Fla.-based company’s Selution SLR drug-eluting balloon (DEB) for both de novo coronary artery stenosis and in-stent restenosis.
RSS
